Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $21.0 million.

  • Ani Pharmaceuticals' Shares Outstanding (Weighted Average) rose 3.13% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.7 million, marking a year-over-year increase of 3.13%. This contributed to the annual value of $21.0 million for FY2024, which is 2.89% up from last year.
  • Ani Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $21.0 million in FY2024, which was up 2.89% from $20.4 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $21.0 million during FY2024, and its lowest value of $12.4 million during FY2020.
  • For the 3-year period, Ani Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $19.6 million, with its median value being $20.4 million (2023).
  • Data for Ani Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 36.96% (in 2022) over the last 5 years.
  • Over the past 5 years, Ani Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $12.4 million in 2020, then rose by 3.18% to $12.8 million in 2021, then soared by 36.96% to $17.5 million in 2022, then grew by 17.02% to $20.4 million in 2023, then rose by 2.89% to $21.0 million in 2024.